StreetInsider.com News Articles

Form 8-K Perspective Therapeutics For: Jun 01

Mon, 01 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26578653.html

Form 8-K Perspective Therapeutics For: Jun 01

Mon, 01 Jun 2026 06:31:00 -0400

si-local-file:///var/storage/secattach/20260601/26578653.html

Form 8-K Perspective Therapeutics For: May 27

Wed, 27 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260527/26558193.html

Form 8-K Perspective Therapeutics For: May 27

Wed, 27 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260527/26558193.html

Form 8-K Perspective Therapeutics For: May 21

Fri, 22 May 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26538043.html

Form 8-K Perspective Therapeutics For: May 21

Fri, 22 May 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260522/26538043.html

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Thu, 21 May 2026 17:51:00 -0400

One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirmed responses out of seven (29%) treated in this cohort of the Phase 1/2a study in heavily pre-treated melanoma; further data expected in late 2026
[²¹²Pb]PSV359 advanced to Cohort 3 of the Phase 1/2a study in FAP-expressing solid tumors; initial safety findings in lower dose cohorts were Grades 1 and 2 only, with no DLTs and no discontinuation due to adverse events; further data expected in late 2026
Updated [212Pb]VMT-α-NET interim efficacy (n=25) and safety data (n=68) as of April 17, 2026, were

Perspective Therapeutics doses first patients in new study cohorts

Mon, 18 May 2026 06:30:19 -0400

Perspective Therapeutics Inc. (NYSE AMERICAN: CATX) announced that first patients have been dosed in new cohorts of two ongoing Phase 1/2a clinical trials.

The company treated the first patient with [212Pb]VMT-α-NET in a fourth cohort of its Phase 1/2a trial for patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. This cohort tests a front-loading approach with a 20 mCi cumulative dose distributed as 6.0 mCi, 5.0 mCi, 5.0 mCi, and 4.0 mCi across four doses.

Additionally, the first patient received [212Pb]PSV359 in a third cohort of the company's Phase 1/2a dose-finding trial for patients with solid tumors expressing

Perspective Therapeutics doses first patients in new study cohorts

Mon, 18 May 2026 06:30:19 -0400

Perspective Therapeutics Inc. (NYSE AMERICAN: CATX) announced that first patients have been dosed in new cohorts of two ongoing Phase 1/2a clinical trials.

The company treated the first patient with [212Pb]VMT-α-NET in a fourth cohort of its Phase 1/2a trial for patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. This cohort tests a front-loading approach with a 20 mCi cumulative dose distributed as 6.0 mCi, 5.0 mCi, 5.0 mCi, and 4.0 mCi across four doses.

Additionally, the first patient received [212Pb]PSV359 in a third cohort of the company's Phase 1/2a dose-finding trial for patients with solid tumors expressing

Perspective Therapeutics doses first patients in new study cohorts

Mon, 18 May 2026 06:30:19 -0400

Perspective Therapeutics Inc. (NYSE AMERICAN: CATX) announced that first patients have been dosed in new cohorts of two ongoing Phase 1/2a clinical trials.

The company treated the first patient with [212Pb]VMT-α-NET in a fourth cohort of its Phase 1/2a trial for patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors. This cohort tests a front-loading approach with a 20 mCi cumulative dose distributed as 6.0 mCi, 5.0 mCi, 5.0 mCi, and 4.0 mCi across four doses.

Additionally, the first patient received [212Pb]PSV359 in a third cohort of the company's Phase 1/2a dose-finding trial for patients with solid tumors expressing